Logo image of TRVI

TREVI THERAPEUTICS INC (TRVI) Stock Fundamental Analysis

USA - NASDAQ:TRVI - US89532M1018 - Common Stock

10.65 USD
-0.04 (-0.37%)
Last: 10/21/2025, 8:00:02 PM
10.65 USD
0 (0%)
After Hours: 10/21/2025, 8:00:02 PM
Fundamental Rating

3

Taking everything into account, TRVI scores 3 out of 10 in our fundamental rating. TRVI was compared to 191 industry peers in the Pharmaceuticals industry. TRVI has a great financial health rating, but its profitability evaluates not so good. TRVI does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TRVI had negative earnings in the past year.
In the past year TRVI has reported a negative cash flow from operations.
TRVI had negative earnings in each of the past 5 years.
TRVI had a negative operating cash flow in each of the past 5 years.
TRVI Yearly Net Income VS EBIT VS OCF VS FCFTRVI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

With a Return On Assets value of -22.12%, TRVI perfoms like the industry average, outperforming 58.12% of the companies in the same industry.
TRVI has a Return On Equity of -23.23%. This is in the better half of the industry: TRVI outperforms 64.40% of its industry peers.
Industry RankSector Rank
ROA -22.12%
ROE -23.23%
ROIC N/A
ROA(3y)-33.18%
ROA(5y)-51.45%
ROE(3y)-36.69%
ROE(5y)-85.71%
ROIC(3y)N/A
ROIC(5y)N/A
TRVI Yearly ROA, ROE, ROICTRVI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TRVI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TRVI Yearly Profit, Operating, Gross MarginsTRVI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, TRVI has more shares outstanding
TRVI has more shares outstanding than it did 5 years ago.
The debt/assets ratio for TRVI has been reduced compared to a year ago.
TRVI Yearly Shares OutstandingTRVI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
TRVI Yearly Total Debt VS Total AssetsTRVI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

TRVI has an Altman-Z score of 77.25. This indicates that TRVI is financially healthy and has little risk of bankruptcy at the moment.
TRVI has a better Altman-Z score (77.25) than 99.48% of its industry peers.
There is no outstanding debt for TRVI. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 77.25
ROIC/WACCN/A
WACCN/A
TRVI Yearly LT Debt VS Equity VS FCFTRVI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 22.40 indicates that TRVI has no problem at all paying its short term obligations.
TRVI has a better Current ratio (22.40) than 92.67% of its industry peers.
A Quick Ratio of 22.40 indicates that TRVI has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 22.40, TRVI belongs to the top of the industry, outperforming 92.67% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 22.4
Quick Ratio 22.4
TRVI Yearly Current Assets VS Current LiabilitesTRVI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for TRVI have decreased by -7.69% in the last year.
EPS 1Y (TTM)-7.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

TRVI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.50% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y15.18%
EPS Next 2Y-4.6%
EPS Next 3Y-12.15%
EPS Next 5Y8.5%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TRVI Yearly Revenue VS EstimatesTRVI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 500M 1B
TRVI Yearly EPS VS EstimatesTRVI Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TRVI. In the last year negative earnings were reported.
Also next year TRVI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TRVI Price Earnings VS Forward Price EarningsTRVI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TRVI Per share dataTRVI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

TRVI's earnings are expected to decrease with -12.15% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.6%
EPS Next 3Y-12.15%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TRVI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TREVI THERAPEUTICS INC

NASDAQ:TRVI (10/21/2025, 8:00:02 PM)

After market: 10.65 0 (0%)

10.65

-0.04 (-0.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05
Inst Owners82.22%
Inst Owner Change0.88%
Ins Owners0.8%
Ins Owner Change0%
Market Cap1.30B
Analysts85.56
Price Target19.98 (87.61%)
Short Float %11.27%
Short Ratio5.31
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.89%
Min EPS beat(2)12.64%
Max EPS beat(2)27.14%
EPS beat(4)3
Avg EPS beat(4)10.37%
Min EPS beat(4)-7.61%
Max EPS beat(4)27.14%
EPS beat(8)5
Avg EPS beat(8)4.6%
EPS beat(12)9
Avg EPS beat(12)11.06%
EPS beat(16)13
Avg EPS beat(16)12.49%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-7.72%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.35%
EPS NY rev (1m)0.3%
EPS NY rev (3m)7.39%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.55
P/tB 6.55
EV/EBITDA N/A
EPS(TTM)-0.42
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0
BVpS1.63
TBVpS1.63
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.12%
ROE -23.23%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.18%
ROA(5y)-51.45%
ROE(3y)-36.69%
ROE(5y)-85.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.25%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 22.4
Quick Ratio 22.4
Altman-Z 77.25
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)181.11%
Cap/Depr(5y)120.67%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25%
EPS Next Y15.18%
EPS Next 2Y-4.6%
EPS Next 3Y-12.15%
EPS Next 5Y8.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-18.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-6.5%
EBIT Next 3Y-20.42%
EBIT Next 5Y-21.48%
FCF growth 1Y-29.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-30.38%
OCF growth 3YN/A
OCF growth 5YN/A